Caris Life Sciences (CAI) Preferred Stock Liabilities (2024 - 2025)
Caris Life Sciences (CAI) posted quarterly Preferred Stock Liabilities of $2.2 billion for Q1 2025, up 1.1% quarter-over-quarter from $2.2 billion in Q4 2024.
Caris Life Sciences (CAI) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Caris Life Sciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $2.2 billion for Q1 2025.
- In Q1 2025, Preferred Stock Liabilities changed N/A year-over-year to $2.2 billion; the TTM figure through Mar 2025 stood at $2.2 billion (changed N/A YoY), while the FY2024 annual figure was $2.2 billion, up 4.53% from the prior year.
- Preferred Stock Liabilities for Q1 2025 stood at $2.2 billion, up from $2.2 billion in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $2.2 billion in Q1 2025, with the low at $2.2 billion in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2.25 Bn |
| Dec 31, 2024 | 2.22 Bn |
| Sep 30, 2024 | 2.20 Bn |
| Jun 30, 2024 | 2.17 Bn |